The Benefit of Simplification From Tipranavir/Ritonavir 500/200 bid to 500/100 bid Guided by Therapeutic Drug MonitoringMorello, Judit PharmD*; Rodríguez-Novoa, Sonia PhD*; Blanco, Francisco PhD*; Vispo, Eugenia PhD†; Barreiro, Pablo PhD†; Gonzalez-Pardo, Gema*; Jiménez-Nácher, Inmaculada PhD*; González-Lahoz, Juan PhD†; Soriano, Vincent PhD†Therapeutic Drug Monitoring: April 2010 - Volume 32 - Issue 2 - pp 242-244 doi: 10.1097/FTD.0b013e3181d3f97f Short Communication Abstract Author Information Despite being among the most potent protease inhibitors, the use of tipranavir (TPV) is hampered by a high pill burden and frequent side effects compared with other boosted protease inhibitors. A total of 10 patients receiving TPV/ritonavir (TPV/RTV) 500/200 for longer than 6 months were randomized to stay on the same dosing schedule or switch to TPV/RTV 500/100. Although all patients on TVP/RTV 500/200 remained stable for the next 12 weeks, 3 out of 5 patients who switched doses experienced benefits in terms of reducing aminotransferases and total cholesterol. Fasting triglycerides were also reduced in 2 of them. Plasma HIV-RNA remained undetectable in all patients, despite the observed decline in TPV trough concentrations. From the *Pharmacokinetic Unit; and †Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain. Received for publication October 20, 2009; accepted January 13, 2010. Correspondence: Dr. Sonia Rodríguez-Nóvoa, PhD, Service of Pharmacy, Hospital Carlos III, Sinesio Delgado 10, 28029 Madrid, Spain (e-mail: email@example.com). © 2010 Lippincott Williams & Wilkins, Inc.